T-Cure - Model 820TCR - Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1)

The Kita-Kyushu Lung Cancer antigen-1 (KK-LC-1) is a cancer/testis antigen (CTA) that is expressed in multiple solid tumors while restricted to germ line cells in normal tissues. T-Cure estimates that KK-LC-1 is expressed in 80% gastric cancer, 75% triple negative breast cancer (TNBC), 45% non-small cell lung cancer (NSCLC) and 40% cervical cancer. 820TCR was isolated from a complete responder patient after Tumor Infiltrating Lymphocytes (TIL) therapy. 820TCR based therapy is undergoing a Phase 1 clinical study at the National Cancer Institute (NCT05035407). T-Cure has licensed the KK-LC-1 TCR from the NIH and has an CRADA collaboration with the NIH to develop KK-LC-1 TCRs in solid tumors.